Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial
Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check11 days agoChange DetectedPadova, Italy is added and Padua, Italy is removed from the Italy study locations.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedNaples, Italy was added to the locations list and Napoli, Italy was removed from the locations list.SummaryDifference0.0%

- Check32 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded Revision: v3.4.2; removed the previous notices including Revision: v3.4.1 related to government funding and operating status.SummaryDifference0.3%

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.